Table 1.
General features of patients with Parkinson’s disease and controls
| Controls n = 19 | PD-NC n = 14 | PD-MCI n = 17 | PDD n = 15 | |
|---|---|---|---|---|
| Age | 68.1 (3.2) | 69.3 (7.6) | 70.6 (4.2) | 75.4 (5.9)*,# |
| Parkinson’s disease evolution (years) | - | 14.1 (3.8) | 15.0 (4.3) | 14.8 (4.5) |
| Gender (% male) | 57.9 | 64.3 | 70.6 | 40 |
| UPDRS-III ‘OFF’ | - | 33.2 (8.7) | 32.5 (10.4) | 51.4 (10.8)*,† |
| UPDRS-III ‘ON’ | - | 13.5 (6.9) | 16.3 (7.6) | 31.2 (12.2)**,†† |
| Hoehn and Yahr | - | 2.5 (0.6) | 3 (0.7) | 3.7 (0.8)*,† |
| LEDD (mg) | - | 1031 (372) | 1158 (430) | 1039 (650) |
| Education (years) | 10.8 (4.7) | 12.8 (3.8) | 9.9 (3.2)*,# | 9.1 (2.3)*,# |
Values are mean (SD).
*P < 0.05 versus cognitively normal patients with Parkinson’s disease (PD-NC).
**P < 0.001 versus cognitively normal patients with Parkinson’s disease.
†P < 0.05 versus patients with Parkinson’s disease with MCI (PD-MCI).
††P < 0.001 versus patients with Parkinson’s disease with MCI.
#P < 0.05 versus control subjects.
LEDD = Levodopa equivalent daily dose was calculated for each patient (Grosset et al., 2004).
PDD = patients with Parkinson’s disease with dementia; UPDRS-III = Unified Parkinson’s Disease Rating Scale motor section.